Parkville, Australia

Tatiana Kolesnik

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tatiana Kolesnik

Introduction

Tatiana Kolesnik is a prominent inventor based in Parkville, Australia. She has made significant contributions to the field of medical research, particularly in the area of immunology. With a total of two patents to her name, Kolesnik's work focuses on therapeutic methods that have the potential to impact cancer treatment.

Latest Patents

Kolesnik's latest patents include innovative methods for the inhibition of cytokine-induced SH2 protein in natural killer (NK) cells. The present invention relates to therapeutic and prophylactic methods based on the inhibition of CIS in NK cells. In particular, it addresses the treatment or prevention of NK-responsive conditions by administering a CIS inhibitor to a subject or by administering CIS-inhibited NK cells. Furthermore, the invention outlines methods for identifying a CIS inhibitor and determining the likelihood of cancer response to treatment with CIS inhibition.

Career Highlights

Tatiana Kolesnik is affiliated with the Walter and Eliza Hall Institute of Medical Research, where she conducts her research. Her work has garnered attention for its potential applications in treating various conditions related to the immune system. Kolesnik's dedication to advancing medical science is evident in her innovative approaches to complex health issues.

Collaborations

Some of her notable coworkers include Nicholas D Huntington and Sandra Elaine Nicholson. Their collaborative efforts contribute to the advancement of research in immunology and cancer treatment.

Conclusion

Tatiana Kolesnik's contributions to medical research through her patents and collaborative work highlight her role as an influential inventor in the field. Her innovative methods for inhibiting cytokine-induced SH2 protein in NK cells have the potential to transform therapeutic approaches to cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…